Igure 3a). Additionally, the extreme patients with URNA + also demonstrated a
Igure 3a). Furthermore, the extreme sufferers with URNA + also demonstrated a greater danger of death than the extreme patients with URNA – , even though the distinction did not attain statistical significance in between URNA – and URNA + groups of extreme patients (Figure 3b). Diagnostics 2021, 11, x FOR PEER Overview 7 of 14 three.three. The Expression of Thrombomodulin (TM) and von Willebrand Factor (vWF) Was Enhanced in Renal Tissues from Dead COVID-19 Patientsthan We discovered that the expression of ,TM and vWF in interstitialdid not attain statistical sigthe severe patients with URNA- even though the difference vessels, glomerular, and nificance amongst Uin kidneys from groups of severe patients (Figure 3b). tubules were greater RNA- and URNA+ COVID-19 sufferers who had died when compared with thosein kidneys from renal carcinoma patients (Figure 4).Figure two. Categorical urinary SARS-CoV-2 in non-severe (NS) comorbidities of COVID-19 patients on admission. (a) The good test price of variable outcomes of laboratory tests and URNA + and S URNA + patients. (b,c) The prevalence of constructive test price of urinary SARS-CoV-2 in non-severe (NS) URNA+ and S URNA+ sufferers. (b,c) The prevalence of hyperhypertension and cardiovascular disease in Extreme (S) URNA – and Extreme URNA + patients. (d,e) The case Tianeptine sodium salt MedChemExpress percentage of tension and cardiovascular disease in Extreme (S) URNA- and Extreme URNA+ patients. (d,e) The case percentage of enhanced enhanced serum MYO and decreased eGFR. in S URNA – and S URNA – sufferers. (f ) The levels of eGFR, serum IgE and serum MYO and decreased eGFR. in S URNA- and S URNA- patients. (f ) The levels of eGFR, serum IgE and serum IgG in S – and S U + sufferers. p 0.05, p 0.01, p 0.001. serum IgG in S U individuals. p RNA p 0.01, p 0.001. 0.05, URNA- and S URNA+RNAFigure 2. Categorical variable results of laboratory tests and comorbidities of COVID-19 sufferers on admission. (a) TheFigure 2. Categorical variable results of laboratory tests and comorbidities of COVID-19 sufferers on admission. (a) The positive test rate of urinary SARS-CoV-2 in non-severe (NS) URNA+ and S URNA+ patients. (b,c) The prevalence of hypertension and cardiovascular disease in Extreme (S) URNA- and Extreme URNA+ patients. (d,e) The case percentage of elevated Diagnostics 2021, 11, 2089 and decreased eGFR. in S URNA- and S URNA- sufferers. (f ) The levels of eGFR, serum IgE and serum IgG in S serum MYO URNA- and S URNA+ patients. p 0.05, p 0.01, p 0.001.7 ofDiagnostics 2021, 11, x FOR PEER REVIEW8 of3.three. The Expression of Thrombomodulin (TM) and von Willebrand Factor (vWF) Was Improved in Renal Tissues from Dead COVID-19 Patients Figure 3. Survival curve curve for indicated groups COVID-19 patients. (a) Survivalcurve for URNA- and URNA+URNA + COVID-19 Figure three. Survival for indicated groups of of COVID-19 sufferers. (a) Survival curve for URNA – and COVID-19 – patients. Green solid line represents URNARNApatients, and red ML-SA1 medchemexpress dotted line represents URNA+ individuals. (b) Survivalglomerular, and patients. Green solid line represents U -that the expression of TM and vWF in RNA + individuals. (b) Survival curve for We identified sufferers, and red dotted line represents U interstitial vessels, curve for – (S URNA-) and S URNA++ server (S U server URNA -URNA RNA – ) and S URNA COVID-19 patients. Green solidsolidrepresents S patients RNA – had died in comparison with COVID-19 in kidneys from COVID-19 URNA S U who individuals, and red tubules have been higher sufferers. Green line line represents – individuals, a.
